Literature DB >> 17483928

[Chemoprevention of prostate cancer. Current status].

B J Schmitz-Dräger1, G Lümmen, R M Schäfer.   

Abstract

Fueled by the results from recently published large interventional trials the topic of chemoprevention of prostate cancer has increasingly attracted the interest of practicing urologists. In this analysis the term"chemoprevention" comprises all agents not included in regular food intake. If possible, the results from interventional studies were considered. Today, it must be accepted as evidence-based that chemoprevention of prostate cancer by 5alpha-reductase inhibition using finasteride is possible. Furthermore, there is increasing evidence that selective estrogen receptor modulators (SERMs) may also have preventive potential. Prospective interventional trials investigating these substances are currently underway. Considering the high incidence and the fact that the diagnosis of prostate cancer has serious impact on the future life of the respective individuals further scientific evaluation of chemoprevention of prostate cancer is mandatory.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483928     DOI: 10.1007/s00120-007-1352-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  17 in total

1.  The prevention of prostate cancer--the dilemma continues.

Authors:  Peter T Scardino
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

Review 2.  Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.

Authors:  Mark A Moyad
Journal:  Urol Oncol       Date:  2004 Nov-Dec       Impact factor: 3.498

3.  Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy.

Authors:  Sara S Strom; Xuemei Wang; Curtis A Pettaway; Christopher J Logothetis; Yuko Yamamura; Kim-Anh Do; Richard J Babaian; Patricia Troncoso
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

4.  Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial.

Authors:  David Price; Barry Stein; Paul Sieber; Ronald Tutrone; James Bailen; Erik Goluboff; Daniel Burzon; David Bostwick; Mitchell Steiner
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

5.  Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer.

Authors:  Arshi Malik; Farrukh Afaq; Sami Sarfaraz; Vaqar M Adhami; Deeba N Syed; Hasan Mukhtar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-28       Impact factor: 11.205

6.  COX-2 inhibition and cancer: experimental findings and clinical correlates.

Authors:  Elizabeth Gail Roberts; Linda Vona-Davis; Dale R Riggs; Barbara J Jackson; Hesam Hohseni; Stanley J Kandzari; David W McFadden
Journal:  W V Med J       Date:  2004 May-Jun

7.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

Authors:  Gerald Andriole; David Bostwick; Otis Brawley; Leonard Gomella; Michael Marberger; Donald Tindall; Sharon Breed; Matt Somerville; Roger Rittmaster
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

8.  The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies.

Authors:  Joseph M Unger; Michael LeBlanc; Ian M Thompson; Charles A Coltman
Journal:  Urol Oncol       Date:  2004 Jul-Aug       Impact factor: 3.498

Review 9.  Update on chemoprevention of prostate cancer.

Authors:  Eric A Klein; Ian M Thompson
Journal:  Curr Opin Urol       Date:  2004-05       Impact factor: 2.309

Review 10.  Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis.

Authors:  S Mahmud; E Franco; A Aprikian
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.